RESULTS For the comparison of statins ( + /- sildenafil ) with placebo ( + /- sildenafil ) , the mean International Index of Erectile Function ( IIEF-5 ) ( the st and ardized mean difference [ SMD ] = 3.23 , 95 % confidence interval [ CI ] = -1.65 to 4.80 , P < 0.0001 ) indicated that statins ( + /- sildenafil ) showed statistically significantly greater improvements in the mean IIEF-5 compared with placebo ( + /- sildenafil ) .
For the comparison of statins plus sildenafil with placebo plus sildenafil , the mean IIEF-5 ( SMD = 3.60 , 95 % CI = 2.64 to 4.56 , P < 0.00001 ) , the IIEF domain ( SMD = 4.88 , 95%CI = 3.01 to 6.74 , P < 0.00001 ) , and the global efficacy question ( odds ratio = 6.44 , 95 % CI = 2.92 to 14.23 , P < 0.00001 ) showed that compared with placebo plus sildenafil , statins plus sildenafil clearly improved erectile function .
CONCLUSIONS This meta- analysis indicates that statins ( + /- sildenafil ) may improve ED compared with placebo ( + /- sildenafil )
INTRODUCTION It is not known if statins will improve symptoms in patients with established erectile dysfunction ( ED ) .
AIM We carried out a systematic review and meta- analysis to assess the effect of statins on ED .
Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study.
PURPOSE We estimated the incidence of  erectile dysfunction in men 40 to 69 years old at study entry during an average 8.8-year followup , and determined how risk varied with age , socioeconomic status and medical conditions . MATERIAL S AND METHODS Data from a r and omly sample d population based longitudinal study of Massachusetts men were analyzed . A total of 1,709 men completed the baseline interview during 1987 to 1989 and 1,156 survivors completed followup from 1995 to 1997 . The analysis sample consisted of 847 men without erectile dysfunction at baseline and with complete followup information .  Erectile dysfunction was assessed by discriminant analysis of 13 questions from a self-administered sexual function question naire and a single global self-rating question . RESULTS The crude incidence rate for erectile dysfunction was 25.9 cases per 1,000 man-years ( 95 % confidence interval [ CI ] 22.5 to 29.9 ) . The annual incidence rate increased with each decade of age and was 12.4 cases per 1,000 man-years ( 95 % CI 9.0 to 16.9 ) , 29.8 ( 24.0 to 37.0 ) and 46.4 ( 36.9 to 58.4 ) for men 40 to 49 , 50 to 59 and 60 to 69 years old , respectively . The age adjusted risk of erectile dysfunction was higher for men with lower education , diabetes , heart disease and hypertension . Population projections for men 40 to 69 years old suggest that 17,781 new cases of erectile dysfunction in Massachusetts and 617,715 in the United States ( white males only ) are expected annually . CONCLUSIONS Although prevalence estimates and cross-sectional correlates of erectile dysfunction have recently been established , incidence estimates were lacking . Incidence is necessary to assess risk , and plan treatment and prevention strategies . The risk of erectile dysfunction was about 26 cases per 1,000 men annually , and increased with age , lower education , diabetes , heart disease and hypertension
RESULTS For the comparison of statins ( + /- sildenafil ) with placebo ( + /- sildenafil ) , the mean International Index of Erectile Function ( IIEF-5 ) ( the st and ardized mean difference [ SMD ] = 3.23 , 95 % confidence interval [ CI ] = -1.65 to 4.80 , P < 0.0001 ) indicated that statins ( + /- sildenafil ) showed statistically significantly greater improvements in the mean IIEF-5 compared with placebo ( + /- sildenafil ) .
For the comparison of statins plus sildenafil with placebo plus sildenafil , the mean IIEF-5 ( SMD = 3.60 , 95 % CI = 2.64 to 4.56 , P < 0.00001 ) , the IIEF domain ( SMD = 4.88 , 95%CI = 3.01 to 6.74 , P < 0.00001 ) , and the global efficacy question ( odds ratio = 6.44 , 95 % CI = 2.92 to 14.23 , P < 0.00001 ) showed that compared with placebo plus sildenafil , statins plus sildenafil clearly improved erectile function .
CONCLUSIONS This meta- analysis indicates that statins ( + /- sildenafil ) may improve ED compared with placebo ( + /- sildenafil )
INTRODUCTION It is not known if statins will improve symptoms in patients with established erectile dysfunction ( ED ) .
AIM We carried out a systematic review and meta- analysis to assess the effect of statins on ED .